Figure 1
Figure 1. Study design. Twenty-four subjects were studied (4 groups of 6). Somatostatin and glucagon were administered to all subjects using the same doses regardless of clamp type. Glucose was infused at variable rates to achieve plasma concentrations of 5 mM (euglycemic clamps) or 12 mM (hyperglycemic clamps). Insulin was infused at 10 mU·m−2 BSA·min−1 (lower insulinemic clamps) or 40 mU·m−2 BSA·min−1 (high insulinemic clamps). In the HinsuEgluc clamp, insulin infusion was increased to 100 mU·m−2 BSA·min−1 at T = 2 hours (“Study protocol”). LPS was infused at T = 0 hours. Measurements were performed at indicated time points.

Study design. Twenty-four subjects were studied (4 groups of 6). Somatostatin and glucagon were administered to all subjects using the same doses regardless of clamp type. Glucose was infused at variable rates to achieve plasma concentrations of 5 mM (euglycemic clamps) or 12 mM (hyperglycemic clamps). Insulin was infused at 10 mU·m−2 BSA·min−1 (lower insulinemic clamps) or 40 mU·m−2 BSA·min−1 (high insulinemic clamps). In the HinsuEgluc clamp, insulin infusion was increased to 100 mU·m−2 BSA·min−1 at T = 2 hours (“Study protocol”). LPS was infused at T = 0 hours. Measurements were performed at indicated time points.

Close Modal

or Create an Account

Close Modal
Close Modal